CAJ | 학술논문

目的：观察环孢素 A（CsA）治疗小儿难治性肾病综合征的临床治疗效果进行讨论和分析。方法：选择208例小儿难治性肾病综合征的患者作为研究对象。随机分为对照组与干预组两组。其中104例患者为对照组，通过常规的治疗方法；另外104例患者为干预组，通过环孢素 A（CsA）的治疗方法。同时，对比干预组和对照组患者在经过治疗后的临床治疗效果以及出现不良反应情况。结果：经过上述实验研究中的数据对比发现，干预组患者的治疗效果明显优于对照组患者的治疗效果，且干预组患者在经过治疗后出现并发症情况的人数也少于对照组患者，两组差异有统计学意义（ P ﹤0.05）。结论：对于小儿难治性肾病综合征采用环孢素 A（CsA）的治疗方法安全可靠，能够有效减少并发症的发生率，提高患者治疗的总有效率。因此，对于小儿难治性肾病综合征的治疗可以采用环孢素 A（CsA）的治疗方式，其治疗效果显著在临床治疗中可以大力推广、使用。
목적：관찰배포소 A（CsA）치료소인난치성신병종합정적림상치료효과진행토론화분석。방법：선택208례소인난치성신병종합정적환자작위연구대상。수궤분위대조조여간예조량조。기중104례환자위대조조，통과상규적치료방법；령외104례환자위간예조，통과배포소 A（CsA）적치료방법。동시，대비간예조화대조조환자재경과치료후적림상치료효과이급출현불량반응정황。결과：경과상술실험연구중적수거대비발현，간예조환자적치료효과명현우우대조조환자적치료효과，차간예조환자재경과치료후출현병발증정황적인수야소우대조조환자，량조차이유통계학의의（ P ﹤0.05）。결론：대우소인난치성신병종합정채용배포소 A（CsA）적치료방법안전가고，능구유효감소병발증적발생솔，제고환자치료적총유효솔。인차，대우소인난치성신병종합정적치료가이채용배포소 A（CsA）적치료방식，기치료효과현저재림상치료중가이대력추엄、사용。
Objective To investigate and analyze the clinical effect of cyclosporine A(CsA)in the treatment of refractory nephrotic syndrome in children. Method 208 cases of children with refractory nephrotic syndrome were selected as the research object. They were di-vided into control group and intervention group randomly. 104 patients of control group used routine treatment method,104 patients of inter-vention group used ciclosporin A( CsA ). At the same time,compared two groups' clinical treatment effect and adverse reac-tions. Results By comparing the data of the above experimental studies,intervention group's treatment effect was significantly better than control group,intervention group's complications after treatment was lower than control group,the difference was statistically significant(P﹤ 0. 05). Conclusion Ciclosporin A(CsA)is safe and reliable in the treatment of children with refractory nephrotic syndrome,and can ef-fectively reduce the incidence of complications,improve the total effective rate of treatment. Therefore,the treatment of children with refrac-tory nephrotic syndrome can be treated with cyclosporine A(CsA),the treatment effect is significantly in the clinic,it can be vigorously promotion and application.